J. Visich

发表

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

H. Lowman, A. Joshi, Y. Deniz, 2008, The AAPS Journal.

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

M. Eisner, J. Matthews, R. Zhu, 2013, The AAPS Journal.

Population modeling of tumor growth inhibition in vivo : application to anticancer drug development

P. Vicini, M. Rogge, M. Dodds, 2004 .

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

T. Singer, D. Danilenko, F. Theil, 2012, mAbs.

Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.

P. Campochiaro, P. Kuebler, Roman G. Rubio, 2014, Ophthalmology.

Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.

P. Nathan, R. Carvajal, Marlana Orloff, 2018 .

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

R. Avery, D. Pieramici, M. Rabena, 2014, British Journal of Ophthalmology.

administration in patients with congenital factor XIII deficiency Safety and pharmacokinetics of recombinant factor XIII-A2

S. Pederson, G. Young, M. Butine, 2013 .

Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.

S. Pederson, G. Young, M. Butine, 2006, Blood.

Preclinical Safety and Pharmacokinetics of Recombinant Human Factor XIII

R. Ponce, K. Lewis, S. Pederson, 2005, Toxicologic pathology.

Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters

J. Marier, E. Clark, J. Cortés, 2013, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

J. Zhi, T. Robak, A. Dmoszyńska, 2012, Journal of clinical pharmacology.

A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis

N. Lane, B. Hsu, J. Visich, 2021, Osteoarthritis and Cartilage.

Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma

M. Dimopoulos, S. Jagannath, R. Vij, 2017, Journal of clinical pharmacology.

Science and Judgment in Establishing a Safe Starting Dose for First‐in‐Human Trials of Biopharmaceuticals

R. Ponce, J. Visich, 2010 .

Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling.

J. Zhi, M. Wenger, Jing Li, 2009 .

Safety, pharmacokinetics, and immunogenicity of single‐dose rFXIII administration to healthy volunteers

S. Pederson, P. Bishop, M. Butine, 2005, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis

A. Munafo, I. Nestorov, O. Papasouliotis, 2008, Journal of clinical pharmacology.

Bioavailability and relative tissue distribution of [125I]‐recombinant human thrombin following intravenous or subcutaneous administration to non‐human primates

K. Lewis, M. Rogge, K. Byrnes-Blake, 2006, Journal of thrombosis and haemostasis : JTH.

Preclinical safety of recombinant human thrombin.

Erika Giste, R. Ponce, S. Pederson, 2007, Regulatory toxicology and pharmacology : RTP.

Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers

M. Butine, L. Zuckerman, J. Visich, 2005, Thrombosis and Haemostasis.

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

J. Cortés, G. Ross, D. R. Wada, 2014, Cancer Chemotherapy and Pharmacology.

Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101

N. Lane, L. Li, Rémi-Martin Laberge, 2020, Osteoarthritis and Cartilage.

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

J. Mansfield, P. Rutgeerts, J. Egen, 2012, Gut.

High-pressure liquid chromatographic assay for the determination of thyrotropin-releasing hormone and its common metabolites in a physiological salt solution circulated through the isolated perfused rat lung.

P. Byron, J. Visich, 1996, Journal of pharmaceutical and biomedical analysis.

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

B. Lum, Chunze Li, D. Heinzmann, 2015, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma.

D. Hurst, A. Yin, J. Visich, 2010 .

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Y. Houvras, S. Jagannath, J. Dey, 2022, Blood.

Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon

D. Allison, Y. Xin, D. Jin, 2013, Cancer Chemotherapy and Pharmacology.

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

J. Baselga, S. Swain, N. Masuda, 2013, Anti-cancer drugs.

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

M. Eisner, J. Matthews, D. D’Argenio, 2013, The AAPS Journal.

Pharmacokinetics and Pharmacodynamics of Anti-BR3 Monoclonal Antibody in Mice

D. Mager, S. Iyer, J. Visich, 2012, Pharmaceutical Research.

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

A. Munafo, I. Nestorov, M. Rogge, 2007, European Journal of Clinical Pharmacology.

Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra

J. Baselga, S. Swain, N. Masuda, 2012 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept.

R. Ponce, S. Dillon, D. Janszen, 2008, Toxicological sciences : an official journal of the Society of Toxicology.

Population pharmacokinetics of recombinant factor XIII in cynomolgus monkeys

P. Vicini, Michael G. Dodds, J. Visich, 2005, The AAPS Journal.

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

J. Baselga, S. Swain, N. Masuda, 2013, Anti-cancer drugs.